Evidence map›Paper›PMID 26406150›Full record

Trial reportThe New England journal of medicine2015

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

Toni K Choueiri, Bernard Escudier, Thomas Powles, Paul N Mainwaring, Brian I Rini, Frede Donskov, Hans Hammers, Thomas E Hutson, Jae-Lyun Lee, Katriina Peltola and 15 more

6 registry-linked trialsOpen access · bronzeAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The New England journal of medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 580 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
580citing papers in PubMed, 11 pooled it
115.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01865747 phase3completednot on this map

A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy

TypeinterventionalSponsorExelixisRan2013 to 2021Enrolled658ConditionsRenal Cell CarcinomaArmsCabozantinib tablets, Everolimus (Afinitor) tablets
NCT03354884 phase2completednot on this mapstarted 2018, after this paper: background citation

caBozantinib in cOllectiNg ductS Renal Cell cArcInoma (BONSAI)

TypeinterventionalSponsorFondazione IRCCS Istituto Nazionale dei Tumori, MilanoRan2018 to 2020Enrolled23ConditionsCollecting Duct Carcinoma (Kidney)Armscabozantinib
NCT03463681 phase2completednot on this mapstarted 2018, after this paper: background citation

A Phase 2 Open Label Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma Pretreated With One immunochecKPOint INhibiTor (Anti PD1/PDL1): the BREAKPOINT Trial

TypeinterventionalSponsorFondazione IRCCS Istituto Nazionale dei Tumori, MilanoRan2018 to 2021Enrolled49ConditionsMetastatic Renal Cell CarcinomaArmsCabometyx
NCT04131543 phase2unknown statusnot on this mapstarted 2019, after this paper: background citation

"Phase II Study to Evaluate the Activity and Safety of Cabozantinib in Pretreated, Advanced RET-rearranged Non-small Cell Lung Cancer Patients: CRETA Trial"

TypeinterventionalSponsorUniversity of BolognaRan2019 to 2022Enrolled25ConditionsNon Small Cell Lung CancerArmsCabozantinib 20 MG, Cabozantinib 40 MG, Cabozantinib 60 MG
NCT05425004 phase2recruitingnot on this mapstarted 2022, after this paper: background citation

A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma

TypeinterventionalSponsorBaptist Health South FloridaRan2022 to 2028Enrolled24ConditionsMeningiomaArmsCabozantinib
NCT07117409 terminatednot on this mapstarted 2020, after this paper: background citation

Retrospective Observational Study on the Safety of Nivolumab in Patients With Metastatic Renal Carcinoma and Renal Failure

TypeobservationalSponsorAzienda USL Reggio Emilia - IRCCSRan2020 to 2025Enrolled81ConditionsMetastatic Renal Cell Carcinoma
3 · Its place in the literature

Who cites it

580 citing papers in PubMed, 11 syntheses or guidelines pooled it, 1,208 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Treatments for renal cell carcinoma: NICE Pilot Treatment Pathways Appraisal.Health technology assessment (Winchester, England) · 2026
    Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. SEOM SOGUG clinical guideline for treatment of kidney cancer (2022).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Guideline
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. LASER: A Phase 2 Trial ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

520 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 20 institutions in 11 countries.

Toni K ChoueiriFrom the Dana-Farber Cancer Institute, Boston (T.K.C., P.W.K.); Institut Gustave Roussy, Villejuif, France (B.E.); Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, London (T.P.); Icon Cancer Care, South Brisbane, QLD, Australia (P.N.M.); Cleveland Clinic, Cleveland (B.I.R.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (H.H.); Texas Oncology-Charles A. Sammons Cancer Center, Baylor University, Dallas (T.E.H.); University of Ulsan College of Medicine (J.-L.L.) and Seoul National University Hospital (B.K.) - both in Seoul, South Korea; Helsinki University Central Hospital Cancer Center, Helsinki (K.P.); Washington University in St. Louis, St. Louis (B.J.R.); Sunnybrook Odette Cancer Centre, Toronto (G.A.B.), and Tom Baker Cancer Centre, Calgary, AB (D.Y.C.H.) - both in Canada; National Institute of Oncology, Budapest, Hungary (L.G.); Hospital de la Santa Creu i Sant Pau, Barcelona (P.M.); Medical University of Vienna, Vienna (M.S.); Exelixis, South San Francisco, CA (A.B-H., C.H., C.S., G.M.S.); University of Texas M.D. Anderson Cancer Center, Houston (N.M.T.); and the Memorial Sloan Kettering Cancer Center, New York (R.J.M.).
Bernard Escudier
Thomas Powles
Paul N Mainwaring
Brian I Rini
Frede Donskov
Hans Hammers
Thomas E Hutson
Jae-Lyun Lee
Katriina Peltola
Bruce J Roth
Georg A Bjarnason
Lajos Géczi
Bhumsuk Keam
Pablo Maroto
Daniel Y C Heng
Manuela Schmidinger
Philip W Kantoff
Anne Borgman-Hagey
Colin Hessel
Christian Scheffold
Gisela M Schwab
Nizar M Tannir
Robert J Motzer
METEOR Investigators
Exelixis (United States) · USAarhus University Hospital · DKBaylor University · USCancer Council Queensland · AUCancer Research UK · GBCleveland Clinic · USDana-Farber Cancer Institute · USHelsinki University Hospital · FIHospital de Sant Pau · ESInstitut Gustave Roussy · FRMedical University of Vienna · ATMemorial Sloan Kettering Cancer Center · USNational Institute of Oncology · HUProstate Cancer Research · GBSeoul National University Hospital · KRSidney Kimmel Comprehensive Cancer Center · USSunnybrook Health Science Centre · CAThe University of Texas MD Anderson Cancer Center · USUniversity of Ulsan · KRWashington University in St. Louis · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundCabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the pathobiology of metastatic renal-cell carcinoma or in the development of resistance to antiangiogenic drugs. This randomized, open-label, phase 3 trial evaluated the efficacy of cabozantinib, as compared with everolimus, in patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy.

methodsWe randomly assigned 658 patients to receive cabozantinib at a dose of 60 mg daily or everolimus at a dose of 10 mg daily. The primary end point was progression-free survival. Secondary efficacy end points were overall survival and objective response rate.

resultsMedian progression-free survival was 7.4 months with cabozantinib and 3.8 months with everolimus. The rate of progression or death was 42% lower with cabozantinib than with everolimus (hazard ratio, 0.58; 95% confidence interval [CI] 0.45 to 0.75; P<0.001). The objective response rate was 21% with cabozantinib and 5% with everolimus (P<0.001). A planned interim analysis showed that overall survival was longer with cabozantinib than with everolimus (hazard ratio for death, 0.67; 95% CI, 0.51 to 0.89; P=0.005) but did not cross the significance boundary for the interim analysis. Adverse events were managed with dose reductions; doses were reduced in 60% of the patients who received cabozantinib and in 25% of those who received everolimus. Discontinuation of study treatment owing to adverse events occurred in 9% of the patients who received cabozantinib and in 10% of those who received everolimus.

conclusionsProgression-free survival was longer with cabozantinib than with everolimus among patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy. (Funded by Exelixis; METEOR ClinicalTrials.gov number, NCT01865747.).

Indexed as

AdultAgedAged, 80 and overAnilidesAntineoplastic AgentsCarcinoma, Renal CellDisease-Free SurvivalEverolimusFemaleHumansKidney NeoplasmsMaleMiddle AgedPyridinesQuality of LifeSirolimusAnilidesAntineoplastic AgentscabozantinibEverolimusPyridinesSirolimus

Identifiers

PMID26406150
PMCPMC5024539
OpenAlexW2237254160

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.